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Abstract 1	
Mechanisms underlying acute mountain sickness (AMS) remain unclear. Corticosteroids are 2	
effective for prevention and treatment suggesting a role for deficient endogenous cortisol. The 3	
cortisol awakening response (CAR), the increase in cortisol secretion over the first 30-45 4	
minutes after morning awakening, better reflects the hypothalamic–pituitary–adrenal (HPA) 5	
axis than single cortisol measurements. We hypothesized that CAR may be altered in AMS-6	
prone persons. Upon arrival at 4,554 m (HA), 81 mountaineers agreed to participate. The 7	
following morning, they gave 3 saliva samples after awakening (S1: 0, S2: 30, S3: 45 min). 8	
AMS was scored with the 1993 Lake Louise Score (LLS, cut-off ≥ 5). Minimally 4 weeks 9	
after descent saliva was recollected by 58 of 81 participants at low altitude (LA); 382 ± 309m, 10	
mean ± SD). Cortisol was quantified by immunoassay. Three cortisol indices were analyzed: 11	
first sample on awakening (S1), CAR (area under curve with respect to S1) and total post 12	
awaking cortisol (AUC-G; area with respect to ground). AMS prevalence was 30%. At HA 13	
compared to LA, S1 (450 ± 190 vs 288 ± 159 ng/dl, p < 0.001) and AUC-G (387 ± 137 vs 276 14	
± 114 ng/dl⋅min, p < 0.001) were greater, but CAR was not (50 ± 100 vs 60 ± 81 ng/dl⋅min, p 15	
= 0.550). AMS+ compared to AMS- participants had higher S1 both at HA (495 ± 209 vs 384 16	
± 176ng/dl, p = 0.016) and LA (354 ± 160 vs 253 ± 142ng/dl, p = 0.015) and lower CAR at 17	
LA (24 ± 87 vs 79 ± 72 ng/dl⋅min, p = 0.013). AUC-G was similar in both groups at HA and 18	
LA. Some indices of salivary cortisol response upon awakening differ between AMS+ and 19	
AMS-, both at HA and LA, suggesting a link between HPA axis homeostasis and AMS.  20	
	 3	
Introduction 1	
Non-acclimatized persons ascending to altitudes >2,500 m risk developing acute mountain 2	
sickness (AMS) (Bärtsch and Swenson 2013; Basnyat and Murdoch 2003; Hackett and Roach 3	
2001). AMS is characterized by headache, nausea, fatigue, dizziness and insomnia (Meier and 4	
others 2017). Symptoms can be incapacitating and AMS can progress to life threatening high 5	
altitude cerebral edema. The mechanisms underlying AMS remain unclear (Bärtsch and 6	
Swenson 2013; Basnyat and Murdoch 2003; Hackett and Roach 2001; Imray and others 2010).  7	
 8	
Oral synthetic corticosteroids such as dexamethasone and prednisone work well for prevention 9	
and treatment of AMS (Basu and others 2002a; Ferrazzini and others 1987; Levine and others 10	
1989; Rock and others 1989; Tang and others 2014) while inhaled synthetic corticosteroids 11	
such as budesonide do not (Berger and others 2017; Lipman and others 2018). Cortisol 12	
deficiency can present with symptoms similar to those of AMS (fatigue, weakness, gastric pain, 13	
nausea, vomiting, dizziness, insomnia) (Arlt and Allolio, 2003). Therefore, impaired cortisol 14	
homeostasis could be involved in AMS (Panesar 2004). Prior studies reported inconsistent 15	
results, perhaps related to the use of single samples taken at some time of the day while cortisol 16	
levels show circadian swings (Sutton 1977; Woods and others 2012). 17	
 18	
The cortisol awakening response (CAR) describes the marked increase in cortisol levels during 19	
the first 30-45 min following morning awakening (Clow and others 2010a; Clow and others 20	
2004; Kudielka and Wüst 2010). It combines a reactivity index (response to awakening, 21	
(Wilhelm and others 2007) with aspects tied to circadian regulation (Clow and others 2010b). 22	
Two main components can be distinguished: a) the first sample (S1), ideally synchronized with 23	
the moment of awakening, representing the endpoint of a pre-awakening increase; and b) the 24	
actual CAR, representing the dynamic of the cortisol increase after awakening. The two 25	
components (S1 and CAR) are inversely related (Stalder and others 2016) and can be combined 26	
as an index of overall cortisol secretion over the post-awakening period by calculating the area 27	
under the curve from ground (AUC-G) (Pruessner and others 2003). Deviations from a typical 28	
CAR pattern are thought to be indicative of hypothalamic–pituitary–adrenal (HPA)	 axis 29	
perturbations (Chida and Steptoe 2009; Kudielka and others 2012). Using the CAR we explored 30	
the HPA-axis in the context of AMS in conditions of acute exposure to high altitude. We 31	
hypothesized that the cortisol awakening response would be impaired in AMS-prone persons. 32	
  33	
	 4	
Methods 1	
Participants 2	
We recruited 102 mountaineers sequentially upon arrival at a mountain hut on the Swiss-Italian 3	
border (Capanna Regina Margherita, 4,554 m) between the 7th and the 22nd of August 2015. 4	
After receiving oral and written information in Italian, French, English or German participants 5	
gave written informed consent. The study was approved by the research ethics commission of 6	
the Canton Vaud in Switzerland and complied with the current version of the Helsinki 7	
declaration. 8	
 9	
Procedures 10	
In the evening after arrival at the hut participants received instructions with emphasis on 11	
respecting the saliva collection procedure and its precise time points (0, 30 and 45 min post-12	
awakening). They then completed a general questionnaire in their preferred language about 13	
personal information, health and medication, acclimatization, history of altitude illness and 14	
physical activity habits. Upon awakening the following morning the participants first sampled 15	
their saliva and then reported to the experimenter. They then scored AMS symptoms with 16	
validated translations of the 1993 Lake Louise Score (LLS) questionnaire (Roach and others 17	
1993). It scores 5 symptoms: 1) headache, 2) gastrointestinal symptoms, 3) fatigue or weakness, 18	
4) dizziness or light-headedness and 5) difficulty sleeping. Each is scored from 0 (not present) 19	
to 3 (severe or incapacitating) and scores are added up for the total score. AMS was defined as 20	
presence of headache and a score ≥ 5. Presence or absence of AMS is presented by AMS+ and 21	
AMS-, respectively. Resting heart rate (HR) and peripheral oxygen saturation (SpO2; CMS50F 22	
pulse oximeter watch, Contec, Qinhuangdao, China) were measured with the participant quietly 23	
sitting. After receiving instructions and material for saliva sampling at their homes the 24	
participants then left the hut. 25	
 26	
Saliva sampling, handling and analysis 27	
Before saliva sampling the participants were asked to rinse their mouth with water. They then 28	
soaked cotton swabs with saliva by moving them around in the mouth for 2 min without 29	
chewing (Salivette, Sarstedt, Nümbrecht, Germany). They had to avoid smoking, eating and 30	
drinking any beverages other than water during the sampling period, and to report on the sample 31	
form if the expected behavior had not been respected (Stalder and others 2016). At HA, upon 32	
awakening the following morning (12 to 18 hours after arrival at 4,554 m), they collected three 33	
saliva samples (S1 at 0, S2 at 30 and S3 at 45 min). The home samples (LA, 382 ± 309m, mean 34	
	 5	
± SD) were to be taken at the earliest 4 weeks after descent and at the same wake-up time as at 1	
HA. HA samples were stored in a freezer at -15°C and then transported to the laboratory on ice. 2	
LA samples were sent to the laboratory on the day of sampling by priority mail in a pre-stamped 3	
envelope. Upon reception by the laboratory all saliva samples were stored at -20°C until 4	
analysis. Saliva cortisol concentration was quantified by enzyme immunoassay using a 5	
commercially available kit according to the manufacturer's recommended protocol 6	
(Salimetrics, State College, PA, USA). On the day of the assay, samples were thawed, vortexed, 7	
and centrifuged at 1,500 × g (3,000 rpm) for 15 minutes. Clear samples were then pipetted in 8	
duplicate into test wells using a 96-wells plate. Measures were performed in duplicate with the 9	
average of each duplicate used as final value. Three cortisol indices were calculated: first 10	
sample on awakening (S1), cortisol awakening response (area under curve with respect to S1, 11	
CAR: {[(S1 + S2)/2] x 30} + {[(S2 + S3)/2] x 15} – [S1x45]) and total post awaking cortisol 12	
levels (area with respect to ground, AUC-G={[(S1 + S2)/2] x 30} + {[(S2 + S3)/2] x 15}) 13	
(Khoury and others 2015). 14	
 15	
Data analysis and statistics 16	
Data were analyzed with Stata (version 15, StataCorp, College Station, Texas, USA) using t-17	
test, Pearson chi2, ANOVA and linear regression, as appropriate; (non-)normality of data 18	
distribution was accounted for. Aggregate data are reported as means ± SD unless indicated 19	
otherwise. The level of significance was set at p < 0.05. 20	
 21	
Results 22	
Study population 23	
At HA 102 participants accepted to participate to the study of whom 69 also collected cortisol 24	
samples at LA. Nine of the participants were experienced mountain guides. Four participants 25	
were excluded from analysis; three because of acetazolamide use and one because of 26	
dexamethasone use. Other participants were excluded due to incomplete AMS data (n = 3) or 27	
technically unmeasurable cortisol levels (HA: n = 15, LA: n = 7). Therefore, data from 81 28	
participants at HA and 58 participants at LA were analyzed. Their characteristics are shown in 29	
Table 1. In this group of mountaineers AMS prevalence at 4,554 m was 30%. 30	
 31	
>>> Table 1 about here <<< 32	
 33	
	 6	
High altitude vs low altitude 1	
Post-awakening cortisol levels (S1 and AUC-G) were significantly higher at HA compared to 2	
LA while CAR was similar between the two altitudes (Figure 1). There were no significant 3	
correlations between HA cortisol indices, AMS compound score, HR or SpO2. There was a 4	
positive correlation between AMS score and heart rate (R = 0.27, p = 0.014) and a negative 5	
correlation between AMS score and SpO2 (R = −0.25, p = 0.025). There were no correlations 6	
between cortisol indices at LA and AMS scores at HA, except a trend for a slight negative 7	
correlation between CAR and AMS scores (R = −0.25, p = 0.063). 8	
 9	
>>> Figure 1 about here <<< 10	
 11	
AMS+ vs AMS- at high altitude 12	
At high altitude, AMS+ participants displayed significantly higher S1 compared to AMS- 13	
participants (495 ± 209, n = 24, vs 389 ± 173 ng/dl, n = 57, p = 0.020). AUC-G tended to be 14	
higher in AMS+ compared to AMS- participants (423 ± 142, n = 24, vs 367 ± 138 ng/dl⋅min, n 15	
= 57, p = 0.097) while CAR was similar between the two groups (52 ± 119, n = 24, vs 75 ± 104 16	
ng/dl⋅min, n = 57, p = 0.389) (Figure 2a).  17	
 18	
No differences in cortisol indices were found between the individual LLS symptom scores (0, 19	
1, 2 or 3) for headache, gastrointestinal symptoms, fatigue and/or weakness and dizziness/ light-20	
headedness. Difficulty of sleeping scores (0, 1, 2 or 3) were accompanied by an overall 21	
significant increase in S1 (0: 380 ± 167, n = 9, 1: 411 ± 190, n = 30, 2: 401 ± 170, n = 37, 3: 22	
695 ± 193, n = 5, p = 0.008). 23	
 24	
>>> Figure 2 about here <<< 25	
 26	
Mountain guides, who presented lower AMS scores compared to all other participants (1.4 ± 27	
1.5, n = 9, vs 3.7 ± 2.0, n = 72, p = 0.002), displayed higher CAR (140 ± 79, n = 9, vs 59 ± 108 28	
ng/dl⋅min, n = 72, p = 0.032) at HA, while S1 and AUC-G were equal (S1: 388 ± 190, n = 9, 29	
	 7	
vs 425 ± 190 ng/dl, n = 72, p = 0.591, AUC-G: 431 ± 94, n = 9, vs 378 ± 145 ng/dl⋅min, n = 1	
72, p = 0.286).    2	
 3	
AMS+ vs AMS- at low altitude 4	
Cortisol indices assessed at LA were different between participants having suffered or not from 5	
AMS at HA. AMS+ participants displayed significantly higher S1 (357 ± 164, n = 20, vs 253 6	
± 142 ng/dl, n = 38, p = 0.014) and lower CAR (24 ± 87, n = 20, vs 79 ± 72 ng/dl⋅min, n = 38, 7	
p = 0.013) compared to AMS- participants, while AUC-G (292 ± 116, n = 20, vs 268 ± 109 8	
ng/dl⋅min, n = 38, p = 0.448) was similar in the two groups (Figure 2b). No differences were 9	
found in HA minus LA (delta) cortisol indices (S1, CAR and AUC-G) between AMS+ and 10	
AMS-. 11	
 12	
When LA cortisol indexes were compared between participants suffering (i.e. score ≥ 1) or not 13	
(score = 0) from each LLS symptom at HA, we found that difficulty sleeping at HA was 14	
associated with a tendency of higher S1 (p = 0.083) but similar AUC and CAR at LA. Suffering 15	
of dizziness at HA was associated with a significantly higher S1 at LA (p = 0.005) and a 16	
tendency for higher AUC (p = 0.079). Cortisol indexes at LA were similar in participants 17	
suffering or not from all other LLS symptoms at HA. 18	
 19	
At LA mountain guides, compared to all other participants, had lower S1 (138 ± 109, n = 5, vs 20	
303 ± 153 ng/dl, n = 53, p = 0.023), equal CAR (88 ± 99, n = 5, vs 57 ± 79 ng/dl⋅min, n = 53, 21	
p = 0.421) and a tendency for lower AUC-G (191 ± 108, n = 5, vs 284 ± 108 ng/dl⋅min, n = 53, 22	
p = 0.072). 23	
 24	
Discussion 25	
We measured the CAR in mountaineers at high and low altitude and compared it between 26	
AMS+ and AMS- participants. We found that S1 and AUC-G but not CAR were increased at 27	
HA compared to LA. In contrast to our initial hypothesis, post-awakening cortisol levels were 28	
increased in AMS+ participants. Even more interestingly, increased S1 and blunted CAR were 29	
also present in AMS+ participants when assessed at low altitude. 30	
 31	
Cortisol and altitude 32	
Studies of cortisol and adrenocorticotropic hormone (ACTH) levels at HA have reported 33	
inconsistent results because of varying altitudes, exposure times, cortisol collection timing and 34	
	 8	
physical exertion levels. Invariant cortisol levels and similar (Bartsch and others 1991) or 1	
increased ACTH levels (Bouissou and others 1988) have been reported after 1 to 5 hours 2	
exposure to hypobaric hypoxia compared to normoxia. Increased cortisol levels have been 3	
observed from the day upon arrival at HA (Park and others 2014) up to 21 days (Basu and 4	
others 2002b; Humpeler and others 1980; Moncloa and others 1968; Richalet and others 1989; 5	
Zaccaria and others 1998), with a return to LA levels after 30 days (Benso and others 2007; 6	
Sawhney and others 1991). Decreased cortisol levels have been reported 15-16 days after 7	
arrival at HA (McLean and others 1989), perhaps due to a different sampling time. Our study 8	
extends these findings by identifying an increased AUC-G but similar CAR at HA compared 9	
to LA. The only other study to have described post-awakening cortisol indices at HA showed 10	
both increased AUC-G and CAR (Park and others 2014).  11	
 12	
Increased cortisol in AMS+  13	
Only few studies looked at (plasma) cortisol levels in relation with AMS. Increased (Bartsch 14	
and others 1988; Richalet and others 1989) or unchanged (Spliethoff and others 2013; Woods 15	
and others 2012) HA cortisol levels have been found in AMS+ compared to AMS- participants. 16	
At LA, these studies reported similar cortisol levels between AMS+ and AMS-, but only single 17	
measures of (plasma) cortisol were reported. The increased S1 and S3 saliva cortisol levels in 18	
AMS+ compared to AMS- participants, about 12 to 18 hours after arrival at HA in our study, 19	
are consistent with previous findings at the same altitude (4,554 m). Increased cortisol plasma 20	
levels at 6 h and 18 h after arrival at HA and similar levels at 42 h were reported in AMS+ 21	
compared to AMS- participants (Bartsch and others 1988). In that study the largest differences 22	
between cortisol levels of both groups were observed 6 hours after arrival at HA. In a later 23	
study, after 5 ± 1 hours upon arrival at HA, those who would develop AMS initially had the 24	
same ACTH and cortisol levels compared to those who would remain healthy, yet they 25	
displayed more pronounced exercise-induced ACTH and cortisol increases (Bartsch and others 26	
1991). In contrast, no differences in (plasma) cortisol were reported by Spliethoff and others 27	
(2013) about 18 hours after arrival at 4,559 m between AMS+ and AMS- participants. No 28	
significant differences between AMS severity and cortisol levels were found in a study 29	
comparing cortisol levels at rest and following 6 hour day treks during ascent from 1,300 to 30	
5,150m (Woods and others 2012). Our present study extends these previous findings by 31	
reporting a tendency for an increased AUC-G and similar CAR between AMS+ and AMS- at 32	
HA. At HA, we further found blunted cortisol awakening curves in AMS+ participants, while 33	
	 9	
in our mountain guides their tendency for AMS resistance (p = 0.074) was associated with a 1	
higher CAR (p = 0.032). 2	
 3	
Our present study, exploring a different aspect of cortisol homeostasis as compared to plasma 4	
levels at some time point, suggest a significant difference between AMS+ versus AMS- 5	
participants. But in contrast to our initial hypothesis, post-awakening cortisol levels were 6	
increased in participants that developed AMS. On the other hand, the data collected from 7	
experienced mountain guides, less prone to AMS suggest that higher CAR at altitude may be 8	
associated with this reduced risk of AMS. 9	
Taken together, these observations suggest that an altered post-awakening cortisol response is 10	
associated with the development of AMS but do not allow us to determine whether altered 11	
cortisol homeostasis is a consequence or a cause leading to AMS. Assessment performed at low 12	
altitude may contribute to solve this question. 13	
 14	
Cortisol differences at LA 15	
Indeed, we found that, at low altitude and arguably sufficiently distant (minimal 4 weeks) from 16	
the previous altitude exposure, participants having suffered from AMS displayed increased S1 17	
and decreased CAR compared to AMS- participants. Mountain guides, who had lower AMS 18	
scores compared to all other participants at high altitude, displayed lower S1 and AUC-G at 19	
low altitude. Furthermore, increased post-awakening cortisol at low altitude was associated 20	
with development of severe insomnia (and possibly dizziness and headache) at high altitude 21	
suggesting a causal role of altered cortisol homeostasis in the pathogenesis of AMS. 22	
 23	
Others reported no LA cortisol differences between AMS+ and AMS- (Bartsch and others 24	
1991; Bartsch and others 1988; Spliethoff and others 2013). However, only single plasma 25	
cortisol measures were obtained. We found at LA, similar to HA, increased S1, blunted saliva 26	
cortisol awakening curves and additionally decreased CAR for AMS+ compared to AMS- 27	
participants. As associations between CAR indices at LA and AMS were observed it is tempting 28	
to speculate that HPA-axis alterations not only accompany AMS symptoms but also play a 29	
causal role in its development. Autonomic nervous system (ANS) dysregulation is thought to 30	
be involved in AMS (Karinen and others 2012). Increased activation of the sympathetic nervous 31	
system was found in AMS+ participants at HA (Bartsch and others 1991; Bartsch and others 32	
1988; Panesar 2004; Woods and others 2011). ANS and HPA-axis responses to stressors are 33	
highly coordinated (Rotenberg and McGrath 2016). In accordance, higher trait-anxiety and 34	
	 10	
higher levels of anxiety before a mountain ascent were reported in climbers susceptible to AMS  1	
and higher trait-anxiety at low altitude was found predictive for severe AMS at high altitude 2	
(Boos and others 2018; Missoum and others 1992). 3	
 4	
AMS and insomnia 5	
We observed increased S1 values in participants reporting severe insomnia at HA. Increased 6	
S1 levels for severe insomnia in our study agree with elevated 24-h urine cortisol excretions in 7	
poor sleepers (Vgontzas and others 1998) and with increased evening and night cortisol levels 8	
found in insomniacs compared to healthy sleepers (Rodenbeck and others 2002; Vgontzas and 9	
others 2001). In sum, insomnia and AMS seem both associated to increased S1. However, it 10	
remains unclear whether it is the sleep loss that drives the cortisol abnormalities or whether a 11	
primarily hyperactive HPA-axis contributes to the development of insomnia (Riemann and 12	
others 2010).  There is ongoing discussion on including insomnia when assessing AMS 13	
(MacInnis and others 2013) and the 2018 version of the LLS questionnaire revision excluded 14	
the sleep item (Roach and others 2018). We therefore also repeated our analysis without the 15	
insomnia item: LLS-3-NS (cut-off  ≥  3). Prevalence of AMS+ was now 34 %. At HA no cortisol 16	
index differences were observed (S1: p = 0.655, S2: p = 0.636, S3: p = 0.333, CAR: p = 0.502, 17	
AUC-G: p = 0.843). At LA a tendency for an increased S1 (p=0.083) and a decreased CAR 18	
(p=0.056) were observed for AMS+ compared to AMS-, but no other cortisol index differences 19	
were seen (S2: p = 0.793, S3: p = 0.903, AUC-G: p = 0.6413). This suggests that sleep 20	
perturbation played an important role in the relationship we found between cortisol and AMS 21	
risk. 22	
 23	
Cortisol or CRF?  24	
Contrary to our hypothesis AMS+ participants had higher cortisol levels than AMS- 25	
participants. Our findings are thus indicative of a difference between AMS+ and AMS- 26	
participants with regard to HPA-axis regulation, but a mechanistic explanation is lacking. 27	
Recent findings suggest that corticotrophin releasing factor (CRF) and the CRF-receptor-1 28	
might be implicated in AMS and high altitude cerebral edema (HACE) (Chen and others 2014; 29	
Song and others 2016).  We speculate that AMS+ participants might have a stronger stress 30	
response to altitude exposure (for unknown reasons), secreting higher levels of CRF, leading 31	
to greater ACTH release in turn leading to higher cortisol levels. These cortisol levels would 32	
be secondary to the stimulation of CRF-receptor-1 and its manifold other effects. Such a 33	
mechanism would allow to understand why dexamethasone works to prevent and treat AMS 34	
	 11	
and HACE, namely by decreasing CRF secretion via negative feedback (Joyce and others 1	
2018). 2	
 3	
Limitations 4	
Several limitations of the present study must be acknowledged. First, we used saliva cortisol as 5	
an index of circulating free cortisol in plasma. Even though the two are strongly related, saliva 6	
sampling procedure and timing can introduce bias (El-Farhan and others 2017). Inaccurate 7	
sampling varies with psychosocial and health factors (Broderick and others 2004; Dimatteo 8	
2004; DiMatteo and others 2000; Golden and others 2014; Kudielka and others 2007). Such 9	
sampling inaccuracy generally induces overestimated S1 and underestimated CAR. Thus 10	
AMS+ may have influenced sampling accuracy. Furthermore, during 1-day studies up to 70% 11	
of CAR is attributable to trait-like covariates (Almeida and others 2009; Hellhammer and others 12	
2007; Ross and others 2014). Second, one third of HA participants did not send in the LA study 13	
material. Our results are therefore not necessarily representative. Also, our sample was not 14	
homogeneous with regard to prior acclimatization. Finally, the connections between sleep 15	
perturbations, HPA-axis regulation and acute exposure to hypoxia need to be better described. 16	
Further studies with larger populations, cortisol sampling monitoring, and strict variable control 17	
are needed to further study HPA axis differences between AMS+ and AMS- persons. 18	
 19	
Conclusions 20	
Our finding of differing morning cortisol dynamics upon awakening between AMS-prone and 21	
AMS-resistant mountaineers, both at low and at high altitude, suggests a potential link between 22	
HPA-axis homeostasis and AMS risk.  23	
	 12	
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Table 1 1	
Population characteristics 
    General AMS+  AMS-  
P-
Value 
A) General          
 Sex: N (%)     
     Men 67 22 (32.8) 45 (67.2) 0.17 
    Women 14 2 (14.3) 12 (85.7)  
 AMS score: N (%)     
     LLS ≥ 5  24 (29.6) 57 (70.4)  
 Age group: N (%)     
     0-24 yr 11 4 (36.4) 7 (63.6) 0.29 
     25-49 yr 56 14 (25) 42 (75)  
     50-75 yr 13 6 (46.2) 7 (53.8)  
     Age: mean ± SD 36 ±12 36 ±13 36 ±11 0.91 
 BMI: mean ± SD (kg/m2) 23 ± 2 23 ±2 23±3 0.45 
 Smoker: N (%) 7 1 (14.3) 6 (85.7) 0.33 
 Home altitude: mean ± SD (kg/m2)  391 ± 321 
348 ± 
219 
410 ± 
356 0.34 
B) Acclimatization           
 Medication: N (%)      
     Aspirin, paracetamol, ibuprofen, sumatriptan 19 7 (36.8) 12 (63.2) 0.43 
 Cumulated altitude slept last 2 nights: N (%)     
     6-10 km 55 15 (27.3) 40 (72.7) 0.50 
     < 6 km 26 9 (34.6) 17 (65.4)  
     Cumulated altitude slep last 2 nights: mean ± SD 6 ±1.7 5.8 ±1.7 6.1 ±1.6 0.44 
 Last time over 2000 m:  N (%)     
     0 - 14 days 61 15 (24.6) 46 (75.4) 0.04 
     ≥ 15 days 18 9 (50) 9 (50)  
    Last time over 2000 m: days, mean ± SD 44 ±132 114 ± 221 14 ± 36 0.01 
 Mountain guide: N (%) 9 1 (11.1) 8 (88.9) 0.20 
C) History           
 Altitude illness: N (%) 14 4 (28.6) 10 (71.4) 0.92 
 Disease: N (%) 26 5 (19.2) 21 (80.8) 0.16 
     Circulatory problems 6 2 (33.3) 4 (66.7)  
     Respiratory problems 13 1 (7.7) 12 (92.3)  
     Neurological problems 7 2 (28.6) 5 (71.4)  
     Other disease 8 2 (25) 6 (75)  
D) Health parameters           
 Heart rate 87 ±13 90 ± 16 85 ± 11 0.12 
 SpO2 79 ± 5 78 ± 5 80 ± 5 0.09 	2	
Means ± SD. P values are for the test of the hypothesis of equality among AMS+ vs AMS-. 3	
Uncompleted questionnaires explain the varying number in group age (n = 80) and last time 4	
over 2000 m (n = 79). 5	 	6	
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Figure legends 1	
 2	
Figure 1: Post-awakening cortisol levels are higher at high altitude compared to low altitude 3	
 4	
Post-awakening cortisol levels at high altitude (HA) and low altitude (LA). Sample 1 = 0 min 5	
post awakening, sample 2 = 30 min, sample 3 = 45 min. Each symbol represents mean ± SEM. 6	
*** = p < 0.001. Data are matched between HA and LA (n=55). 7	
  8	
Figure 2: Differences in post-awakening cortisol indices between AMS+ and AMS- at high 9	
altitude and low altitude 10	
 11	
Post-awakening cortisol indices; S1, S2, S3, CAR and AUC-G at high altitude and low altitude 12	
between AMS+ and AMS- at HA (Lake Louise Score, cut-off ≥5). Sample 1 = 0 min post 13	
awakening (S1), sample 2 = 30 min (S2), sample 3 = 45 min (S3). CAR: cortisol awakening 14	
response, area under curve with respect to S1. AUC-G: total post awakening cortisol, area under 15	
curve with respect to ground. Each symbol or bar represents the mean ± SEM. b = p < 0.1, * = 16	
p < 0.05. HA (n=81), LA (n=58). 17	
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